Vernal Keratoconjunctivitis (VKC) is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. It is an IgE‐ and T cell‐mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte, and structural cell activation are involved. The disease may present in three clinical forms: tarsal, limbal, and the mixed form.
DelveInsight's "Vernal keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Vernal keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Vernal keratoconjunctivitis market report also covers emerging drugs, current treatment practices, Vernal keratoconjunctivitis market share of the individual therapies, current and forecasted Vernal keratoconjunctivitis Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Vernal keratoconjunctivitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Vernal Keratoconjunctivitis may represent as 3% of serious ophthalmic disease. In addition, the prevalence is about 1 in 5000 cases of eye disease in Northern Europe and North America.
A Japanese epidemiologic study (Uchio EKimura et al, 2008) showed that VKC accounted for 4% of all ocular allergies with a low mean age of patients and severe clinical presentation.
According to the World Allergy Organization, males are more frequently affected than females, with a ratio of 3:1. The disease usually begins before the age of 10 years and remits at the time of puberty, although the age of affected individuals ranges from 3 to 25 years of age.
The Vernal keratoconjunctivitis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Vernal keratoconjunctivitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Vernal keratoconjunctivitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The Vernal keratoconjunctivitis epidemiology section covers insights about historical and current Vernal keratoconjunctivitis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The Vernal keratoconjunctivitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vernal keratoconjunctivitis market or expected to get launched in the market during the study period. The analysis covers Vernal keratoconjunctivitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
For more information on Vernal keratoconjunctivitis Market, visit:https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market